Skip to main content

Year: 2023

Urinary Flow Meters Market Size to Surpass USD 34.9 Million by 2030, exhibiting a CAGR of 8.3%

As per the report by Fortune Business Insights, the global urinary flow meters market size is projected to reach USD 34.9 million in 2030, at a CAGR of 8.3% during the forecast period, 2023-2030Urinary Flow Meters MarketUrinary Flow Meters Market Forecast, 2023-2030Pune, India, Oct. 19, 2023 (GLOBE NEWSWIRE) — The global urinary flow meters market size is projected to grow from USD 19.9 million in 2023 to USD 34.9 million by 2030, exhibiting a CAGR of 8.3% during the forecast period. Urinary flow meters are used in hospitals and specialty clinics to evaluate the diagnosis of different urological conditions. Fortune Business Insights™ mentioned this in a report titled, “Urinary Flow Meters Market, 2023-2030.” Key Industry Development- April 2023 – MINZE HEALTH participated in the American Urology Association Meeting...

Continue reading

Wearable Medical Devices Market Size to Surpass USD 428.92 Billion by 2030, at a CAGR of 28.6%

As per the report by Fortune Business Insights, the global Wearable Medical Devices Market size is projected to reach USD 428.92 billion in 2030, at a CAGR of 28.6% during the forecast period, 2023-2030Wearable Medical Devices MarketWearable Medical Devices Market Forecast, 2023-2030Pune, India, Oct. 19, 2023 (GLOBE NEWSWIRE) — The global Wearable Medical Devices Market Size was valued at USD 59.12 billion in 2022 and is projected to grow USD 428.92 billion by 2030, exhibiting a CAGR of 28.6% during forecast period. The rising health consciousness among people is a major factor that will drive the wearable medical devices market growth. This information is provided by Fortune Business Insights™ in its research report titled Wearable Medical Devices Market, 2023-2030. Key Industry Development-May 2023: Indian...

Continue reading

Microprocessor Market Size to Surpass USD 100.15 Billion by 2030, exhibiting a CAGR of 10.3%

As per the report by Fortune Business Insights, the global microprocessor market size is projected to reach USD 100.15 billion by 2030, at a CAGR of 10.3% during the forecast period.Microprocessor MarketForecast, 2023-2030Pune, India, Oct. 19, 2023 (GLOBE NEWSWIRE) — The global microprocessor market size was valued at USD 50.55 billion in 2022 and is projected to reach USD 100.15 billion by 2030, exhibiting a CAGR of 10.3% during the forecast period. Fortune Business Insights has provided this information in its latest research report titled, “Microprocessor Market Forecast, 2023-2030”. Microprocessors are Integrated Circuits (ICs) that act as the Central Processing Unit (CPU) of a computer system. They carry out arithmetic and logical operations and also execute complex instructions.Request a Sample PDF:    https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/microprocessor-market-108504Key...

Continue reading

Form 8.3 – [EMIS GROUP PLC 18 10 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Europe Facial Injectable Market Size to Surpass USD 3.14 Billion by 2030, exhibiting a CAGR of 6.0%

As per the report by Fortune Business Insights, the Europe Facial Injectable Market size is projected to reach USD 3.14 billion by 2030, at a CAGR of 6.0% during the forecast periodEurope Facial Injectable MarketForecast, 2023-2030Pune, India, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Europe facial injectable market size was USD 1.98 billion in 2022, and it is projected to grow from USD 2.08 billion in 2023 to USD 3.14 billion by 2030, exhibiting a CAGR of 6.0% during the forecast period. Facial injectables are substances injected under the skin to enhance the skin by minimizing the wrinkles on the skin. The increasing demand for the product is attracting prominent players to invest in R&D activities to augment market growth and the development of novel products. This information is provided by Fortune Business Insights...

Continue reading

Nordic American Tankers Ltd (NYSE: NAT) – Purchase of suezmax tanker – increasing the NAT fleet to 20 ships

Thursday October 19, 2023   Dear Shareholders and investors,   NAT is pleased to announce that today we entered into a purchase agreement for a suezmax tanker. The vessel was built by a yard in South Korea and has been operated and well maintained by a top shipowner the last 6 to 7 years. The vessel is purchased on a charter free basis and we intend to finance the purchase with a sale leaseback financing – an arrangement that has worked very well for us in the past. This purchase will increase our fleet to 20 suezmaxes. The vessel will be included in our fleet within this quarter, entering a strong market for our ships. We expect the vessel to generate positive cashflow and be a dividend contributor from day one. Sincerely, Herbjorn HanssonFounder, Chairman & CEO Nordic American Tankers Ltd.                                       ...

Continue reading

Festi hf: Forecast updated based on preliminary accounts for Q3 2023

According to preliminary management accounts for Q3 2023, EBITDA will be ISK 3.9 billion compared to ISK 3.1 billion for the same period last year which is an increase of ISK 0.8 billion YoY.  In light of stronger Q3 results than previously anticipated and updated management forecast for the remainder of the year, EBITDA forecast for the full year 2023 is increased from ISK 9,750 – 10,250 million to ISK 10,400 – 10,800 million. Festi will publish the Q3 2023 results on Wednesday 25 October after closing of markets. An investor meeting will be held on Thursday 26 October 2023, at 8:30 am GMT, at the Company´s headquarters at Dalvegur 10 – 14, Kópavogur. For further information, please contact Ásta S. Fjeldsted, CEO of Festi –  asta@festi.is or Magnús Kr. Ingason, CFO of Festi – mki@festi.is

Continue reading

21Shares in another regional first with Shariah compliant digital asset ETPs

A year since listing the region’s first digital asset exchange traded product (ETP) on the Nasdaq Dubai, 21Shares secures Shariah approval for its market leading ETPs.ZURICH/RIYADH, October 19 2023: 21Shares, the world’s largest issuer of digital asset ETPs, continues its international expansion with Shariah approval of its 21Shares Bitcoin ETP (ABTC) and21Shares BOLD ETP (BOLD) from leading Saudi scholars. Having launched the world’s first crypto backed ETP in 2018, the company continues to lead the market with the expansion of its products and a catalogue of listings on major global exchanges. Amidst sustained interest from Saudi investors, the recent Shariah compliance of the BOLD ETP is significant in that the product is at the forefront to become Saudi Arabia’s first hybrid product. Rebalanced monthly, BOLD has a 25:75 Bitcoin to...

Continue reading

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

Tampere Heart Hospital FinlandOctober 19, 2023 Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital’s (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint. The results of the analysis have been translated into a joint action plan that will help Heart Hospital accelerate its decarbonization efforts in line with Finland’s world-leading commitment to reach net zero emissions by 2035. “Sustainability is an integral part of Tampere...

Continue reading

Atos to deliver foundational IT services to Special Olympics until 2027

Official signing on October 10, 2023, in Washington, DCTim Shriver, Special Olympics International, ChairmanNovie Craven, Special Olympics International & D.C. AthleteNacho Moros, Atos, COO, Major GamesMalcolm Andrews, Special Olympics D.C. AthleteJavier Escudero, Atos, Partnerships DirectorMary Davis, Special Olympics International, CEOPress release Atos to deliver foundational IT services to Special Olympics until 2027 Paris, France and Washington DC, United States – October 19, 2023 – Atos today announces its partnership with Special Olympics, Inc. (Special Olympics), a global nonprofit organization that promotes understanding, acceptance, and inclusion among people with and without intellectual disabilities through sporting activities.  As part of this partnership, Atos will provide several foundational digital services...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.